Close
Xylem
Novotech

Research Insight

Oramed releases Phase IIa trial of ORMD-0801 to treat type 2 diabetes

Oramed Pharmaceuticals has released results of a Phase IIa clinical trial of its ORMD-0801, an oral insulin capsule for the treatment of type 2 diabetes. The trial was carried out under a US...

Immuneering Corporation Expands Alliance with Bristol-Myers Squibb

Immuneering Corporation announced today that it has entered into an agreement to expand its existing relationship with Bristol-Myers Squibb for the use of Immuneeringโ€™s proprietary computational biology methods to identify biological insights that may facilitate discovery...

IMI Builds Collaborations to Monitor Vaccine Safety and Drug Effectiveness

The Innovative Medicines Initiative (IMI) is calling experts to join forces and tackle two challenges which are of major importance to public health. Measuring the combined benefits and risks of vaccines and assessing the effectiveness of...

Warfarin and aspirin are similar in heart failure treatment

In the largest and longest head-to-head comparison of two anti-clotting medications, warfarin and aspirin were similar in preventing deaths and strokes in heart failure patients with normal heart rhythm, according to late-breaking research presented at the American Stroke Association's...

Researchers Refine Nanoparticles For More Accurate Delivery Of Cancer Drugs

A new class of nanoparticles, synthesized by a UC Davis research team to prevent premature drug release, holds promise for greater accuracy and effectiveness in delivering cancer drugs to tumors. The work is published in the current issue...

Mylan introduces new antiepileptic drug

Mylan Institutional business has launched Levetiracetam in Sodium Chloride Injection of multiple strengths, 500mg/100ml, 1000mg/100ml and 1500mg/100ml, for intravenous use. Levetiracetam in sodium chloride injection is an antiepileptic drug indicated for adults with different...

Vidacare study reveals IO infusion equivalent to IV in Therapeutic Hypothermia

Vidacare's study to compare Intraosseous (IO) vascular access to infuse chilled saline as effectively as peripheral intravenous (IV) access to achieve therapeutic hypothermia showed no statistical difference between the two routes. ย  The study was named...

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Must read

Translate ยป